TMEFF2 mod 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JNJ-8902 / J&J, Genmab
NCT06788509: A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitation
1
80
Europe, Japan, RoW
JNJ-75348780, JNJ-67856633, safimaltib, JNJ-54179060, ibrutinib, JNJ-64264681, JNJ-74856665, JNJ-70218902, JNJ-64619178
Janssen Research & Development, LLC
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Solid Tumor, Adult, Metastatic Castration-resistant Prostate Cancer (mCRPC)
01/28
01/28
NCT04397276: A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Active, not recruiting
1
82
Europe, Canada, RoW
JNJ-70218902
Janssen Research & Development, LLC
Neoplasms
06/25
10/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JNJ-8902 / J&J, Genmab
NCT06788509: A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitation
1
80
Europe, Japan, RoW
JNJ-75348780, JNJ-67856633, safimaltib, JNJ-54179060, ibrutinib, JNJ-64264681, JNJ-74856665, JNJ-70218902, JNJ-64619178
Janssen Research & Development, LLC
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Solid Tumor, Adult, Metastatic Castration-resistant Prostate Cancer (mCRPC)
01/28
01/28
NCT04397276: A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Active, not recruiting
1
82
Europe, Canada, RoW
JNJ-70218902
Janssen Research & Development, LLC
Neoplasms
06/25
10/25

Download Options